Associate Professor, Radiation Oncology, University of Washington School of Medicine
Radiation Oncology
Dr. Kent E. Wallner, MD
|
|
Give Review
Kent Wallner is an expert in the field of Radiation Oncology. He studied medicine at The Ohio State University College of Medicine. Kent Wallner is a published doctor. He published 99 publications, including: 'Is supplemental external beam radiation therapy essential to maximize bracytherapy outcomes in patients with unfavorable intermediate-risk disease?'
Publications
- Is supplemental external beam radiation therapy essential to maximize bracytherapy outcomes in patients with unfavorable intermediate-risk disease?
- Long-term outcomes of prostate cancer patients with Gleason pattern 5 treated with combined brachytherapy and external beam radiotherapy.
- Commentary on "Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: Implications for prostate brachytherapy"
- Gleason score 7 prostate cancer treated with interstitial brachytherapy with or without supplemental external beam radiation and androgen deprivation therapy: is the p...
- 20 Gy Versus 44 Gy of Supplemental External Beam Radiotherapy with Palledium-103 for Patients with Greater Risk Disease: Results of a Prospective Randomized Trial.
- The Impact of Diabetes Mellitus on Survival in Men With Clinically Localized Prostate Cancer Treated With Permanent Interstitial Brachytherapy.
- Higher percentage of positive biopsy cores and Gleason score are associated with a greater degree of prostate gland shrinkage after neoadjuvant cytoreductive therapy.
- Erectile dysfunction is predictive of all-cause mortality in patients with prostate cancer treated with permanent interstitial brachytherapy.
- Distant Metastases Following Permanent Interstitial Brachytherapy for Patients With Clinically Localized Prostate Cancer.
- Serum Testosterone Kinetics After Brachytherapy for Clinically Localized Prostate Cancer.
- Electromagnetic transponders indicate prostate size increase followed by decrease during the course of external beam radiation therapy.
- Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy.
- The correlation between annular treatment margins and biochemical failure in prostate brachytherapy patients with optimized intraprostatic dosimetry.
- Greater biopsy core number is associated with improved biochemical control in patients treated with permanent prostate brachytherapy.
- High-Risk Prostate Cancer With Gleason Score 8-10 and PSA Level ≤15 ng/ mL Treated With Permanent Interstitial Brachytherapy.
- Androgen deprivation therapy: a survival benefit or detriment in men with high-risk prostate cancer?
- Point: Prostate carcinoma treatment for the young patient--the case for brachytherapy.
- Electromagnetic tracking of intrafraction prostate displacement in patients externally immobilized in the prone position.
- Permanent prostate brachytherapy in prostate glands <20 cm(3).
- Whole-pelvis radiotherapy in combination with interstitial brachytherapy: does coverage of the pelvic lymph nodes improve treatment outcome in high-risk prostate cancer?
- Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy.
- Factors impacting all-cause mortality in prostate cancer brachytherapy patients with or without androgen deprivation therapy.
- Obesity does not correlate with adverse pathologic findings on transperineal template-guided mapping biopsy of the prostate.
- Erectile function durability following permanent prostate brachytherapy.
- Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy.
- Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB.
- Biochemical and functional outcomes following brachytherapy with or without supplemental therapies in men < or = 50 years of age with clinically organ-confined pros...
- Prostate brachytherapy in men > or =75 years of age.
- Primary causes of death after permanent prostate brachytherapy.
- Interstitial brachytherapy should be standard of care for treatment of high-risk prostate cancer.
- Role of trospium chloride in brachytherapy-related detrusor overactivity.
- Obesity is not predictive of overall survival following permanent prostate brachytherapy.
- PSA spike after brachytherapy For localized prostate cancer.
- Technologic evolution in the treatment of prostate cancer. Clinical, financial, and legal implications for managed care organizations.
- The impact of acute urinary morbidity on late urinary function after permanent prostate brachytherapy.
- Intraoperative ultrasound-fluoroscopy fusion can enhance prostate brachytherapy quality.
- Isotope and patient age predict for PSA spikes after permanent prostate brachytherapy.
- Dosimetry of an extracapsular anulus following permanent prostate brachytherapy.
- Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam.
- A prospective randomized comparison of stranded vs. loose 125I seeds for prostate brachytherapy.
- Long-term rectal function after permanent prostate brachytherapy.
- Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United St...
- Prostate brachytherapy seed migration to the right coronary artery associated with an acute myocardial infarction.
- Treatment of prostate cancer in obese patients.
- Temporal relationship between prostate brachytherapy and the diagnosis of colorectal cancer.
- Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer.
- Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy.
- Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy.
- Commentary on "Medical malpractice in the age of technology: how specialty societies can make a difference (Anscher and Anscher)".
- Risk factors for the development of prostate brachytherapy related urethral strictures.
- Permanent prostate brachytherapy: is supplemental external-beam radiation therapy necessary?
- The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
- Selecting patients with pretreatment postvoid residual urine volume less than 100 mL may favorably influence brachytherapy-related urinary morbidity.
- Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized ...
- Prognostic significance of perineural invasion on biochemical progression-free survival after prostate brachytherapy.
- Intraoperative fluoroscopic dose assessment in prostate brachytherapy patients.
- Nursing considerations in brachytherapy-related erectile dysfunction.
- Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.
- Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
- Prostate cryotherapy: more questions than answers.
- Erectile function after prostate brachytherapy.
- Enzymatic prostatic acid phosphatase in the clinical staging of patients diagnosed with prostate cancer.
- The impact of primary Gleason grade on biochemical outcome following brachytherapy for hormone-naive Gleason score 7 prostate cancer.
- Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
- The impact of radiation dose to the urethra on brachytherapy-related dysuria.
- Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis.
- Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
- Permanent interstitial brachytherapy for clinically organ-confined high-grade prostate cancer with a pretreatment PSA < 20 ng/mL.
- Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
- Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
- Morbidity after brachytherapy for prostate adenocarcinoma.
- The impact of prostate volume and neoadjuvant androgen-deprivation therapy on urinary function following prostate brachytherapy.
- Treatment margins predict biochemical outcomes after prostate brachytherapy.
- Patient selection for prostate brachytherapy: more myth than fact.
- Effect of cigarette smoking on biochemical outcome after permanent prostate brachytherapy.
- Prognostic significance of percent positive biopsies in clinically organ-confined prostate cancer treated with permanent prostate brachytherapy with or without supplem...
- Temporal effect of neoadjuvant androgen deprivation therapy on PSA kinetics following permanent prostate brachytherapy with or without supplemental external beam radia...
- Effect of transurethral resection on urinary quality of life after permanent prostate brachytherapy.
- Influence of hormonal therapy on late rectal function after permanent prostate brachytherapy with or without supplemental external beam radiotherapy.
- The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy.
- Postradiotherapy surveillance practice for head and neck squamous cell carcinoma--too much for too little?
- Minimizing prostate brachytherapy-related morbidity.
- Extracapsular radiation dose distribution after permanent prostate brachytherapy.
- Late rectal function after prostate brachytherapy.
- Isodose patterns in patients with inadequate prostate brachytherapy coverage.
- Comparison of MRI pulse sequences in defining prostate volume after permanent implantation: in regard to McLaughlin et al., IJROBP 2002;54:703-711.
- Long-term urinary quality of life after permanent prostate brachytherapy.
- Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland.
- Dysuria after permanent prostate brachytherapy.
- Rectal function following brachytherapy with or without supplemental external beam radiation: results of two prospective randomized trials.
- Management of sexual dysfunction after prostate brachytherapy.
- Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy.
- Ultrasonography and fluoroscopic fusion for prostate brachytherapy dosimetry.
- The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction.
- Prostate-specific antigen spikes after permanent prostate brachytherapy.
- Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
- Penile bulb imaging.
- The Case for Hypofractionation of Localized Prostate Cancer.
Schools
Ohio State University College of Medicine
Cook County Hospital
Doctors Specialties
- Radiation Oncology
Accepted Insurances
Education
-
UCSF Medical Center -
John H. Stroger Hospital of Cook County -
The Ohio State University College of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Daniel M. Landis, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Li-Ming Fang, MD |
|
|
Dr. Janice N. Kim, MD |
|
|
Dr. Tobias R. Chapman, MD |
|
|
Dr. Gabrielle M. Kane, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas D. Mullen, MD |
|
|
Dr. Jing S. Zeng, MD
This Doctor is OpenDoctor Recommended.
|